Ab­b­Vie snaps up a bis­pe­cif­ic for mul­ti­ple myelo­ma in TeneoOne buy­out; Ver­tex launch­es $1.5B share buy­back pro­gram

Fol­low­ing a pos­i­tive in­ter­im Phase I read­out, Ab­b­Vie is ex­er­cis­ing an op­tion to ac­quire TeneoOne and its BC­MA can­di­date TNB-383B for re­lapsed or re­frac­to­ry mul­ti­ple myelo­ma.

Ab­b­Vie inked a deal with TeneoOne back in 2019 to de­vel­op and com­mer­cial­ize TNB-383B, a bis­pe­cif­ic an­ti­body that tar­gets BC­MA and CD3. The treat­ment is de­signed to di­rect the body’s im­mune sys­tem against BC­MA-ex­press­ing tu­mor cells. And ac­cord­ing to in­ter­im re­sults, the can­di­date showed a 79% ob­jec­tive re­sponse rate in a Phase I study. Six­ty-three per­cent of pa­tients saw a “very good par­tial re­sponse” or bet­ter, and 29% saw a com­plete re­sponse at dos­es greater than or equal to 40 mg at a me­di­an fol­low-up of 6.1 months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER